Literature DB >> 2219751

Foveating saccades.

S G Whittaker1, R W Cummings.   

Abstract

A review of the literature revealed that foveating saccades were found to be faster than other fast eye movements (FEMs) except optokinetic nystagmus (OKN) quick phase. In the present experiment, foveating saccades were compared to OKN quick phase in humans and were found to have higher maximum speeds and shorter durations. Unlike previous experiments, foveating saccades were made to targets at unpredictable distances, and active pursuit during OKN was discouraged. Previously reported differences between the speeds of foveating saccades and saccades to remembered target positions were replicated. Foveating saccades, therefore, can be distinguished from other FEMs on the basis of speed. This behavioral difference suggests that a distinctive mechanism exists for foveating targets.

Entities:  

Mesh:

Year:  1990        PMID: 2219751     DOI: 10.1016/0042-6989(90)90009-a

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  4 in total

1.  Characteristics of braking saccades in congenital nystagmus.

Authors:  Jonathan B Jacobs; Louis F Dell'Osso; R John Leigh
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

2.  Combining fixation and lateral masking training enhances perceptual learning effects in patients with macular degeneration.

Authors:  Marcello Maniglia; Vincent Soler; Yves Trotter
Journal:  J Vis       Date:  2020-10-01       Impact factor: 2.240

3.  We don't all look the same; detailed examination of peripheral looking strategies after simulated central vision loss.

Authors:  Marcello Maniglia; Roshni Jogin; Kristina M Visscher; Aaron R Seitz
Journal:  J Vis       Date:  2020-12-02       Impact factor: 2.240

4.  A method to characterize compensatory oculomotor strategies following simulated central vision loss.

Authors:  Marcello Maniglia; Kristina M Visscher; Aaron R Seitz
Journal:  J Vis       Date:  2020-09-02       Impact factor: 2.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.